Sunday 18 October 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.72
0.02
−1.15%
Follow BDTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
19.23% | 22.88% | (35.16%) | (37.21%) | |
| 14.54% | 16.84% | (27.95%) | (29.21%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
17.26% | 19.11% | (39.73%) | (42.61%) | |
Free Cash Flow per Share |
0.38 | 0.52 | (0.59) | (0.57) | |
Free Cash Flow |
21.38 | 29.64 | (34.03) | (32.84) | |
Capital Expenditures |
0.03 | 0.03 | — | — | |
| Other line items | |||||
Cash ROIC |
8.17% | 12.31% | (15.29%) | (15.89%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.99 | 1.32 | 0.79 | 0.77 | |
Depreciation/Fixed assets |
0.31 | 0.89 | 0.78 | 0.67 | |
Capex/Depreciation |
0.09 | 0.08 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.38 | 0.52 | (0.59) | (0.57) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates